These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 12895386)

  • 41. Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma.
    Santos ES; Kharfan-Dabaja MA; Ayala E; Raez LE
    Leuk Lymphoma; 2006 Dec; 47(12):2453-76. PubMed ID: 17169792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Radio-immunotherapy in low-grade non-Hodgkin's lymphoma.
    Lemieux B; Coiffier B
    Best Pract Res Clin Haematol; 2005 Mar; 18(1):81-95. PubMed ID: 15694186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].
    de Nully Brown P; Jurlander J; Lindén O; Hansen M
    Ugeskr Laeger; 2005 Oct; 167(41):3867-9. PubMed ID: 16221425
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma.
    Meredith RF; Knox SJ
    Int J Radiat Oncol Biol Phys; 2006; 66(2 Suppl):S15-22. PubMed ID: 16979433
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Radioimmunotherapy with 90Y-ibritumomab tiuxetan in lymphomas].
    Setoain X; López-Guillermo A; Ruiz A; Pons F
    Rev Esp Med Nucl; 2006; 25(1):55-68; quiz 69-70.. PubMed ID: 16540015
    [No Abstract]   [Full Text] [Related]  

  • 46. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
    Witzig TE; White CA; Wiseman GA; Gordon LI; Emmanouilides C; Raubitschek A; Janakiraman N; Gutheil J; Schilder RJ; Spies S; Silverman DH; Parker E; Grillo-López AJ
    J Clin Oncol; 1999 Dec; 17(12):3793-803. PubMed ID: 10577851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Contribution of radioimmunotherapy to the treatment of lymphoma].
    Rizzo-Padoin N
    Ann Pharm Fr; 2008; 66(5-6):300-8. PubMed ID: 19061730
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radioimmunotherapy for non-Hodgkin's lymphoma with yttrium 90 ibritumomab tiuxetan.
    Hendrix CS; de Leon C; Dillman RO
    Clin J Oncol Nurs; 2002; 6(3):144-8. PubMed ID: 11998607
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Yttrium 90 ibritumomab tiuxetan in lymphoma.
    Cheung MC; Haynes AE; Stevens A; Meyer RM; Imrie K;
    Leuk Lymphoma; 2006 Jun; 47(6):967-77. PubMed ID: 16840185
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues.
    Silverman DH; Delpassand ES; Torabi F; Goy A; McLaughlin P; Murray JL
    Cancer Treat Rev; 2004 Apr; 30(2):165-72. PubMed ID: 15023434
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nursing a patient during and after 90Y-ibritumomab tiuxetan (Zevalin) therapy.
    Clayton J
    Leuk Lymphoma; 2003; 44 Suppl 4():S49-55. PubMed ID: 15154742
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
    Friedberg JW; Fisher RI
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin).
    Hernandez MC; Knox SJ
    Semin Oncol; 2003 Dec; 30(6 Suppl 17):6-10. PubMed ID: 14710397
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
    Schnell R; Dietlein M; Schomäcker K; Kobe C; Borchmann P; Schicha H; Hallek M; Engert A
    Onkologie; 2008 Feb; 31(1-2):49-51. PubMed ID: 18268399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
    Wiseman GA; Leigh BR; Erwin WD; Sparks RB; Podoloff DA; Schilder RJ; Bartlett NL; Spies SM; Grillo-López AJ; Witzig TE; White CA
    Cancer Biother Radiopharm; 2003 Apr; 18(2):165-78. PubMed ID: 12804042
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of ibritumomab tiuxetan radioimmunotherapy for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Witzig TE
    Semin Oncol; 2000 Dec; 27(6 Suppl 12):74-8. PubMed ID: 11226003
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of radiolabeled antibodies in the treatment of non-Hodgkin's lymphoma: the coming of age of radioimmunotherapy.
    Goldenberg DM
    Crit Rev Oncol Hematol; 2001; 39(1-2):195-201. PubMed ID: 11418316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Radioimmunotherapy of relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
    Dillman RO
    Curr Hematol Rep; 2003 Jan; 2(1):30-7. PubMed ID: 12901152
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists.
    Macklis RM; Pohlman B
    Int J Radiat Oncol Biol Phys; 2006 Nov; 66(3):833-41. PubMed ID: 16965871
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Yttrium-90 (90Y) ibritumomab tiuxetan (Zevalin) induces long-term durable responses in patients with relapsed or refractory B-Cell non-Hodgkin's lymphoma.
    Wiseman GA; Witzig TE
    Cancer Biother Radiopharm; 2005 Apr; 20(2):185-8. PubMed ID: 15869453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.